Osagie Imasogie, VP and Director of GSK Ventures, explains that his group is just like any other venture capital firm focused on deploying assets to maximize returns to investors. But rather than investing cash in up-and-coming businesses and duplicating the efforts of the many and varied cash-based VCs in the market, including GlaxoSmithKline PLC 's corporate venture capital arm, SR One Ltd., Ventures instead invests non-core assets from GSK's R&D operations.
Imasogie believes that Ventures has found a niche. There's already plenty of cash in VCs' pockets to back promising companies,...




